Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia

T J Kipps1

  • 1Department of Medicine, University of California, San Diego, La Jolla 92093-0663, USA.

Current Opinion in Hematology
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Recent advancements in chronic lymphocytic leukemia (CLL) research include identifying genetic abnormalities, understanding cell behavior, and improving therapies like purine analogues and bone marrow transplantation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Leukemia·2017
Same author

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.

Leukemia·2017
Same author

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.

Leukemia·2017
Same author

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Leukemia·2017
Same author

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.

Leukemia·2016
Same author

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Leukemia·2016
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Chronic lymphocytic leukemia (CLL) research has seen significant progress in understanding its cytogenetics and biology.
  • Key genetic abnormalities in CLL are being further defined, suggesting the potential discovery of a new tumor suppressor gene.

Purpose of the Study:

  • To review recent advancements in the cytogenesis, biology, and therapy of chronic lymphocytic leukemia (CLL).
  • To highlight the implications of genetic abnormalities for prognosis and treatment strategies.
  • To discuss new insights into immune pathophysiology and emerging therapeutic options for CLL.

Main Methods:

  • Review of recent studies on cytogenetic abnormalities in CLL.
  • Analysis of research on leukemia cell phenotype, drug resistance, and surface antigens.

Related Experiment Videos

  • Examination of studies on immune pathophysiology and clinical trials of purine analogues.

    • Main Results:

    • Identification of relationships between genetic abnormalities and CLL cell phenotype/drug resistance, aiding prognosis.
    • Improved understanding of surface antigens influencing leukemia cell infiltration.
    • Verification of purine analogue efficacy in multicenter trials.
    • Consideration of novel therapies like bone marrow and gene therapy.

    Conclusions:

    • Continued progress in understanding CLL genetics and biology offers new therapeutic avenues.
    • Genetic profiling and understanding immune mechanisms are crucial for personalized CLL treatment.
    • Emerging therapies hold promise for improved patient outcomes in chronic lymphocytic leukemia.